Drug Company Attorneys Urge More Government Scrutiny of 340B

by Admin | September 18, 2013 1:17 pm

September 18, 2013—Health care providers in the 340B drug discount program should be subject to far more government scrutiny and drug companies should have more power to look at 340B covered entities’ books, attorneys who represent drug companies in 340B matters said during a major drug industry conference in Chicago last week.

You must be registered to read complete articles (it's quick, easy, and 100% free). Click here to register[1]. Already registered? Click here to login[2]. (340B Health members, Drug Discount Monitor subscribers, and 340B Coalition conference attendees: Use your existing username and password.)

Endnotes:

Click here to register: https://secure.340bhealth.org/340Binformed/Subscribe.aspx
Click here to login: http://340binformed.org/reader-login/

Source URL: https://340binformed.org/2013/09/drug-company-attorneys-urge-more-government-scrutiny-of-340b/